To the Editor The recent Research Letter1 comparing 2 cell-free DNA next-generation sequencing tests in prostate cancer has severe methodological flaws. It improperly confuses clinicians and implies that laboratory accreditation standards are lax. Published cell-free DNA test concordance study design criteria2 include:
Agarwal N, Lanman RB, Pal SK. Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. JAMA Oncol. 2018;4(10):1429–1430. doi:10.1001/jamaoncol.2018.2317
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: